Literature DB >> 26622501

Association among the expression of β-catenin, cyclin D1 and estrogen receptor-β in human breast cancer.

Liying Guo1, Dilimina Yilamu1, Liting Sun1, Sha Liu1, Fangjing Ma1.   

Abstract

β-catenin, cyclin D1 and estrogen receptor (ER)-β are closely associated with the pathogenesis of breast cancer. In the present study, tissue samples were collected from 226 patients with breast cancer. Subsequently, immunohistochemical analysis was performed to detect the expression of β-catenin, cyclin D1 and ER-β, and the Kaplan-Meier method was used for survival analysis. The abnormal expression rate of β-catenin was 75.2%, while the cyclin D1 positive expression rate was 77.0% and the ER-β positive expression rate was 43.4%. In the tissue samples exhibiting abnormal expression of β-catenin, the positive expression rate of cyclin D1 (85.9%) was significantly higher compared with the samples that expressed β-catenin normally (50.0%). Furthermore, the positive expression rate of ER-β (35.7%) in the β-catenin normal expression tissues was significantly lower compared with that in the β-catenin abnormal expression tissues (45.9%). In the tissues with positive cyclin D1 expression, the positive expression rate of ER-β (48.4%) was significantly higher compared with the cyclin D1 negative expression samples (26.9%). In addition, patients with normal expression of β-catenin and positive expression of cyclin D1 exhibited longer tumor-free survival times. Therefore, an association exists among the abnormal expression of β-catenin and the positive expression of cyclin D1 and ER-β, which may contribute to the development of breast cancer.

Entities:  

Keywords:  Wnt signaling pathway; cyclin D1; estrogen receptor-β; human breast cancer; β-catenin

Year:  2015        PMID: 26622501      PMCID: PMC4578070          DOI: 10.3892/etm.2015.2657

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  28 in total

1.  Cloning of a novel receptor expressed in rat prostate and ovary.

Authors:  G G Kuiper; E Enmark; M Pelto-Huikko; S Nilsson; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  CDK-independent activation of estrogen receptor by cyclin D1.

Authors:  R M Zwijsen; E Wientjens; R Klompmaker; J van der Sman; R Bernards; R J Michalides
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

3.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

4.  CYCLIN D1 as a genetic modifier in hereditary nonpolyposis colorectal cancer.

Authors:  S Bala; P Peltomäki
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

5.  Estrogen receptor-α drives adiponectin effects on cyclin D1 expression in breast cancer cells.

Authors:  Loredana Mauro; Michele Pellegrino; Francesca Giordano; Emilia Ricchio; Pietro Rizza; Francesca De Amicis; Stefania Catalano; Daniela Bonofiglio; Maria Luisa Panno; Sebastiano Andò
Journal:  FASEB J       Date:  2015-02-05       Impact factor: 5.191

6.  Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein.

Authors:  S Bates; D Parry; L Bonetta; K Vousden; C Dickson; G Peters
Journal:  Oncogene       Date:  1994-06       Impact factor: 9.867

7.  Cyclin D1 and prognosis in human breast cancer.

Authors:  C Gillett; P Smith; W Gregory; M Richards; R Millis; G Peters; D Barnes
Journal:  Int J Cancer       Date:  1996-04-22       Impact factor: 7.396

8.  Study of phospho-beta-catenin subcellular distribution in invasive breast carcinomas in relation to their phenotype and the clinical outcome.

Authors:  Lydia Nakopoulou; Eleni Mylona; Ioanna Papadaki; N Kavantzas; I Giannopoulou; S Markaki; A Keramopoulos
Journal:  Mod Pathol       Date:  2006-04       Impact factor: 7.842

Review 9.  Wnt signalling via the epidermal growth factor receptor: a role in breast cancer?

Authors:  Elizabeth A Musgrove
Journal:  Breast Cancer Res       Date:  2003-10-24       Impact factor: 6.466

10.  The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer.

Authors:  Emmi Peurala; Peppi Koivunen; Kirsi-Maria Haapasaari; Risto Bloigu; Arja Jukkola-Vuorinen
Journal:  Breast Cancer Res       Date:  2013-01-21       Impact factor: 6.466

View more
  6 in total

1.  MicroRNA-520b affects the proliferation of human glioblastoma cells by directly targeting cyclin D1.

Authors:  Xuchang Liu; Fachen Wang; Lin Tian; Tongxin Wang; Wei Zhang; Ben Li; Yun-An Bai
Journal:  Tumour Biol       Date:  2015-12-23

Review 2.  Wnt/β-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.

Authors:  Malak El Sabeh; Subbroto Kumar Saha; Sadia Afrin; Md Soriful Islam; Mostafa A Borahay
Journal:  Mol Cell Biochem       Date:  2021-05-17       Impact factor: 3.842

3.  MicroRNA-216a suppresses the proliferation and migration of human breast cancer cells via the Wnt/β-catenin signaling pathway.

Authors:  Qing Xie; Shuai Wang; Yue Zhao; Zhenchao Zhang; Chuan Qin; Xianjun Yang
Journal:  Oncol Rep       Date:  2019-03-07       Impact factor: 3.906

4.  Estrogen receptor subtype agonist activation in human cutaneous squamous cell carcinoma cells modulates expression of CD55 and Cyclin D1.

Authors:  Jing Lan; Xing-Hua Gao; Rashmi Kaul
Journal:  EXCLI J       Date:  2019-08-08       Impact factor: 4.068

5.  Transformation of nomifensine using ionizing radiation and exploration of its anticancer effects in MCF-7 cells.

Authors:  Seong Hee Kang; Dong-Ho Bak; Byung Yeoup Chung; Hyoung-Woo Bai
Journal:  Exp Ther Med       Date:  2022-02-23       Impact factor: 2.447

6.  High-frequency deregulated expression of Wnt signaling pathway members in breast carcinomas.

Authors:  Zahid Khan; Maha Arafah; Jilani Purusottapatnam Shaik; Alka Mahale; Mohammad Saud Alanazi
Journal:  Onco Targets Ther       Date:  2018-01-11       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.